Literature DB >> 6459338

Decreased suppressor T-lymphocytes in autoimmune thyroid diseases detected by monoclonal antibodies.

V Sridama, F Pacini, L J DeGroot.   

Abstract

Monoclonal antibodies reacting with cell surface antigens of helper (T4), suppressor (T8) T cells and common T-cell antigen (T3) were used by an immunofluorescence technique to enumerate peripheral T-lymphocytes in 42 patients with Graves' disease and 16 patients with Hashimoto's thyroiditis. The percentages of total T cells (cells which react with anti-T3) and helper/inducer cells (cells which react with anti-T4) among peripheral mononuclear cells in Graves' and Hashimoto's patients were not significantly different from those found in normal controls, except for a decrease in cells which react with anti-T3 in toxic Graves' disease without medication. The most important finding was a decrease in the percentage of cytotoxic/suppressor T cells (cells which react with anti-T8) in toxic Graves' disease and Hashimoto's thyroiditis. In patients with Graves' disease who were hyperthyroid or euthyroid on propylthiouracil treatment and euthyroid after radioactive iodide treatment, the percentage of cells which react with anti-T8 was also decreased, but this did not reach statistical significance. These findings support the hypothesis of defects in suppressor T-lymphocytes in autoimmune thyroid diseases.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6459338     DOI: 10.1210/jcem-54-2-316

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Lymphocytes in peripheral blood and thyroid tissue in children with Graves' disease.

Authors:  Ben-Skowronek Iwona; Sierocinska-Sawa Jadwiga; Korobowicz Elzbieta; Szewczyk Leszek
Journal:  World J Pediatr       Date:  2008-12-23       Impact factor: 2.764

2.  Studies on suppressor T lymphocyte function in Graves' disease by 3H-thymidine interpolation.

Authors:  W Y Fang; W X Ye
Journal:  J Tongji Med Univ       Date:  1987

3.  Surface expression and release of soluble forms of CD8 and CD23 in CD40- and IL-4-activated mononuclear cells from patients with Graves' disease (GD).

Authors:  M Itoh; K Uchimura; N Hayakawa; M Makino; R Hayashi; M Nagata; H Kakizawa; A Nagasaka; H Sakamoto; H Kuzuya
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

4.  Quantitative immunological differences between newly diagnosed Graves' disease patients and relapsed patients.

Authors:  U Di Mario; F P Cavatorta; R Perfetti; G Pugliese; P Pozzilli; J Sutherland; M Vitillo; D Andreani
Journal:  J Endocrinol Invest       Date:  1988-02       Impact factor: 4.256

5.  Induction of in vitro autoimmune responses by mononuclear blood cells in Hashimoto's thyroiditis.

Authors:  S A Stern; P C Dau
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

6.  Endocrine regulation of the immune system.

Authors:  W Kiess; B H Belohradsky
Journal:  Klin Wochenschr       Date:  1986-01-02

7.  Immunohistological phenotyping of thyroid infiltrating lymphocytes in Graves' disease and Hashimoto's thyroiditis.

Authors:  T Misaki; J Konishi; T Nakashima; Y Iida; K Kasagi; K Endo; T Uchiyama; K Kuma; K Torizuka
Journal:  Clin Exp Immunol       Date:  1985-04       Impact factor: 4.330

8.  Detection of HLA-DR antigens in paraffin-embedded thyroid epithelial cells with a monoclonal antibody.

Authors:  R V Lloyd; T L Johnson; M Blaivas; J C Sisson; B S Wilson
Journal:  Am J Pathol       Date:  1985-07       Impact factor: 4.307

9.  Analysis of T cell subsets in Graves' disease: alterations associated with carbimazole.

Authors:  M E Ludgate; A M McGregor; A P Weetman; S Ratanachaiyavong; J H Lazarus; R Hall; G W Middleton
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

10.  Effect of carbimazole treatment on specific and non-specific immunological parameters in patients with Graves' disease.

Authors:  J Charreire; G Karsenty; P Bouchard; G Schaison
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.